AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI

RecruitingNAAges 18 Years - anyAllNorth Karelia Central Hospital
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to compare DCB with DES in stable CAD or ACS patients who are at high risk of bleeding. The hypothesis of the DEBATE trial is that the strategy using DCB and a shorter DAPT regimen is non-inferior to the treatment using DES and longer DAPT duration on patients with high bleeding risk. If non-inferiority is shown, the superiority of the DCB strategy over DES strategy will be tested.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years * Informed written consent * At least one major or two minor bleeding risk criteria of Academic Research Consortium (ARC) Major Criteria * Long-term oral anticoagulation * Severe or end stage chronic kidney disease (CKD) (estimated glomerular - filtration rate \[eGFR\] \<30 ml/min) * Hemoglobin \<110 g/l * Spontaneous bleeding requiring hospitalization and transfusion in the past 6 months * Moderate to severe baseline thrombocytopenia (platelet count \<100 x 10e9/L) * Chronic bleeding diathesis * Liver cirrhosis with portal hypertension * Active cancer in the past 12 months * Previous spontaneous ICH (at any time) * Previous traumatic ICH within the past 12 months * Presence of known brain arteriovenous malformation * Moderate to severe ischemic stroke within the past 6 months * Nondeferrable major surgery on dual antiplatelet therapy * Recent major surgery or trauma within 30 days before PCI Minor Criteria * Age \>75 years * Moderate CKD (eGFR 30-59 ml/min) * Hemoglobin 110-129 g/l for men and 110-119 g/l for women * Spontaneous bleeding requiring hospitalization or transfusion within the past 12 - months not meeting major criterion * Long term use of oral nonsteroidal antiinflammatory drugs or steroids * Any ischemic stroke at any time not meeting major criterion Either of the following: 1. Stabile angina or dyspnea and a coronary narrowing causing myocardial ischemia detected in the angiogram. In stable patients prior PCI, the evidence of ischemia is needed acquired either by perfusion imaging or by pressure wire measurement (FFR) during coronary angiography unless the coronary stenosis is \> 90% in diameter. 2. ACS (UAP or NSTEMI): symptoms of heart ischemia≥ 20 minutes and ≥ 0,5mm ST-depression or transient ST-elevation or T-wave inversion at least in two adjacent leads and/or a high sensitivity troponin (hs-tnt) rise at least one unit above the 99. percentil or at least 50% rise in hs-tnt between two samples taken 1-3 hours apart. At least one of the following: * ≥1 de novo lesions in native coronary arteries or bypass vein grafts * Reference diameter of the vessel is 2.0-5.0mm' * Lesion length ≤ 40mm * Lesion or lesions are suitable for PCI Exclusion Criteria: * Inability to give written consent * STEMI * Reference diameter of the vessel is \<2.0mm or \>5.0 mm * Bifurcation lesion requiring the stenting of either of the branches after predilatation (TIMI\<3 or significant recoil \>30% in the main epicardial vessel: LAD, LCX or RCA) after predilatation) * Dissection affecting the flow (TIMI\<3) or significant recoil (\>30% in the main epicardial vessel: LAD, LCX or RCA) after predilatation * in-stent restenosis * Chronic total occlusion * Life expectancy \< 12 months * Cardiogenic shock at the arrival to the coronary angiography * Uncertainty about neurological recovery e.g. after resuscitation * Need for bypass surgery by heart team decision
💊

What it tests

  • Percutaneous coronary intervention using drug-coated balloon
  • Percutaneous coronary intervention using drug-eluting stent
📍

Where

14 sites
Central Hospital of Central Finland
Jyväskylä, Finland
Central Hospital of Lapland
Rovaniemi, Finland
Kuopio University Hospital
Kuopio, Finland
Turku University Hospital
Turku, Finland
Helsinki University Hospital
Helsinki, Finland
North Karelia Central Hospital
Joensuu, Finland
Central Hospital of Päijät-Häme
Lahti, Finland
Oulu university hospital
Oulu, Finland

…and 6 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy